Concept:
Tumor Lysis Syndrome (TLS) occurs most frequently in hematologic malignancies characterized by high tumor burden, rapid cell proliferation rates, and exquisite chemosensitivity to cytotoxic induction therapy.
Explanation:
• Among the pediatric cancers listed, Acute Lymphoblastic Leukemia (ALL) has a high proliferative rate and large tumor burden (often presenting with marked leukocytosis, hyperleukocytosis $> 100,000/\mu\text{L}$, massive hepatosplenomegaly, and generalized lymphadenopathy).
• The rapid destruction of lymphoblasts during the initial phases of cytotoxic induction chemotherapy causes immediate release of large quantities of potassium, intracellular phosphorus, and nucleic acids (which metabolize into uric acid) into systemic circulation.
• Burkitt lymphoma and T-cell ALL have the highest overall incidence and risk stratification for spontaneous and post-treatment tumor lysis syndrome.
• Hodgkin lymphoma is a slow-growing indolent lymphoma with low tumor proliferative rate, where neoplastic Reed-Sternberg cells comprise only a small minority ($1\text{--}2\%$) of the tumor mass, making TLS exceptionally rare.
• Chronic Myeloid Leukemia (CML) is a chronic myeloproliferative disorder that progresses indolently and rarely undergoes acute massive lysis unless in accelerated or blast crisis.
• Wilms tumor is a solid renal tumor and solid tumors have a much lower cellular turnover and chemosensitivity profile, rarely precipitating acute tumor lysis syndrome.
Final Answer:
Among the given options, Acute Lymphoblastic Leukemia (ALL) is the most common cause of clinically significant tumor lysis syndrome.